In order to accelerate innovation and commercialize products, strong alliances between pharmaceutical companies have become the norm in the industry in recent years
.
Recently, a large number of domestic and foreign pharmaceutical companies have announced cooperation
in new drugs and talent training.
On October 24, Salubris signed a cooperation agreement
with Shenzhen AlphaMolecular Technology Co.
, Ltd.
(AlphaMol) to jointly develop new drugs.
The two parties will carry out in-depth R&D cooperation in the field of anti-obesity new drug research and development, use AI (artificial intelligence) to jointly promote the intelligent upgrading of drug research and development, and accelerate the benefits of patients
with innovation.
The collaboration will combine Salubris' expertise in drug discovery, development and clinical translation with Alpha Molecular's powerful biocomputing, artificial intelligence and original biotechnology to accelerate the discovery of drug molecules
for potential anti-obesity targets.
It is understood that this is the first foreign cooperation of Salubris to lay out the AI drug research and development track, or will help the upgrading and transformation of drug research and
development technology.
On October 20, Chengdu Lead Drug Development Co.
, Ltd.
and pioneering drug discovery company C4X Discovery Holdings plc (AIM: C4XD, "C4XD") announced a collaboration to discover novel small molecule emergent compounds targeting inflammatory diseases for further development
of C4XD.
Chengdu Lead has been committed to the development and application of
DNA-encoded compound library technology (DEL).
C4XD, on the other hand, is a highly innovative company that has developed a range of valuable pipelines through its proprietary Conformetrix technology
.
It is understood that the cooperation between the two parties aims to further expand C4XD's growing pipeline of small molecule compounds in the field of inflammation and export candidate compounds
for preclinical development and licensing transfer.
On October 18, biotech company Ikena Oncology announced that it has entered into a clinical trial cooperation agreement with AstraZeneca to evaluate Tagrisso (osimertinib) and Ikena IK-930 as a treatment for
patients with EGFR-mutated non-small cell lung cancer.
It is understood that ongoing clinical trials will explore different targeted therapy combinations
through a cohort program.
One of the cohorts will focus on the potential of
IK-930 to overcome resistance to EGFR inhibitors.
On October 17, biotechnology company Kineta, Inc.
announced a collaboration agreement with Merck to combine the investigational antibody KVA12123 with Keytruda (pembrolizumab) as a potential treatment for
advanced solid tumors.
On October 10, CR Pharma announced a strategic cooperation
with Fosun Pharma.
According to the content of the cooperation, the two parties will carry out comprehensive cooperation in the field of general health, focusing on innovative drugs, biological drugs, medical devices and other fields through strategic and business cooperation, to strengthen the global layout and industrialization development
of both parties in related fields.
In addition to the strong cooperation between pharmaceutical companies to cooperate in the development of new drugs, some pharmaceutical companies have chosen to cooperate
with schools in talent training and medical services.
For example, on October 25, Tongrentang Group and Beijing University of Chinese Medicine signed a strategic cooperation agreement, after the signing of this strategic cooperation agreement, the two sides will further deepen cooperation in talent training, research and technology transformation, medical services, cultural inheritance and international cooperation on the basis of the original cooperation
.
At the same time, the two sides will also set up a special working organization to promote the implementation of cooperation and achieve results
.
From the current point of view, strong alliances between pharmaceutical companies have become very common
in the industry.
It is understood that since the beginning of this year, innovative pharmaceutical companies have been setting off a wave of cooperation, and the amount of cooperation involved is also growing
.
Among them, it is worth noting that while enterprise cooperation is becoming more frequent, new drugs are obviously still the focus
of enterprise cooperation.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
